Interleukin-2 therapy of metastatic renal cell carcinoma: Update of phase III trials

Clinical Genitourinary Cancer

Volumn 5, Issue 2, 2006, Pages 114-119

  McDermott, David F ^a,b   Regan, Meredith M ^a   Atkins, Michael B ^a  

^a DANA FARBER HARVARD CANCER CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Carbonic anhydrase IX; Complete remission; Cytokine therapy; Interferon

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 2;

HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS;

EID: 36148991669     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.027     Document Type: Review

References (43)

1. Linehan WM, Bates SE, Yang JC. Cancers of the kidney. In: DeVita VT Jr, ed. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2005.
2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353:2477-2490.
3. Motzer RJ, Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 178:2530-2540.
4. Yagoda A., Petrylak D., Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993; 20:303-314.
5. Pyrhonen S., Salminen E., Lehtonen T., et al. Recombinant interferon alfa-2a with vinblastine vs. vinblastine alone in advanced renal cell carcinoma: a phase III study. Proc Am Soc Clin Oncol 1996; 15:244 (Abstract #614).
6. Muss HB, Costanzi JJ, Leavitt R., et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 1987; 5:286-291.
7. Yang JC, Haworth L., Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434.
8. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitar-geted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patient with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24.
9. Fyfe G., Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688-696.
10. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recom-binant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6: S55-S57.
11. Rosenberg SA, Yang JC, White DE, et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Identification of the antigens mediating response. Ann Surg 1998; 228:307-319.
12. Belldegrun A., Webb DE, Austin HA III, et al. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. J Urol 1989; 141:499-503.
13. Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989; 7:486-498.
14. Sleijfer DT, Janssen RA, Buter J., et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992; 10:1119-1123.
15. Lopez Hanninen E., Kirchner H., Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996; 155:19-25.
16. Yang JC, Topalian SL, Parkinson D., et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994; 12:1572-1576.
17. Atzpodien J., Lopez Hanninen E., Kirchner H., et al. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 1995; 13:497-501.
18. Figlin RA, Belldegrun A., Moldawer N., et al. Concomitant administration of recom-binant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992; 10:414-421.
19. Negrier S., Escudier B., Lasset C., et al. Recombinant human interleukin-2, re-combinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338:1272-1278.
20. Vogelzang NJ, Lipton A., Figlin RA. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 1993; 11:1809-1816.
21. Atzpodien J., Kirchner H., Hanninen EL, et al. Interleukin-2 in combination with interferon alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993; 29A:S6-S8.
22. Yang JC, Sherry RM, Stienberg SM, et al. A three-arm randomized comparison of high and low dose intravenous and subcutaneous interleukin-2 in the treatment of metastatic renal cancer. J Clin Oncol 2003; 21:3127-3132.
23. McDermott D. F., Regan MM, Clark JI, et al. A randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-141.
24. Negrier S., Perol D., Ravaud C., et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma of intermediate prognosis? Results of the pro-spectively randomized PERCY Quattro trial. J Clin Oncol 2005; 23(16 suppl):380s (Abstract #LBA4511).
25. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interluekin-2 in patients with high-risk renal cell carcinoma - a Cytokine Working Group phase III trial. Proc Am Soc Clin Oncol 2003; 22:164 (Abstract #659).
26. Pantuck AJ, Zisman A., Dorey F., et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003; 97:2995-3002.
27. Besana C., Borri A., Bucci E., et al. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous α-interferon. Eur J Cancer 1994; 9:1292-1298.
28. Rosenberg SA, Lotze M. T., Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7:1863-1874.
29. Figlin R., Gitlitz B., Franklin J., et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 1997; 3:S92.
30. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 98:2566-2575.
31. Royal RE, Steinberg SM, Krouse RS, et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am 1996; 2:91.
32. Atkins MB, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with inter-leukin-2 and lymphokine-activated killer cells. N Engl J Med 1988; 318:1557-1563.
33. Fumagalli LA, Vinke J., Hoff W., et al. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 2003; 26:394-402.
34. West WH, Tauer KW, Yanelli JR, et al. Constant-infusion recombinant inter-leukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316:898-905.
35. Janik JE, Sznol M., Urba WJ, et al. Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors. Cancer 1993; 72:2656-2659.
36. Negrier S., Escudier B., Gomez F., et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francias d'Immunotherapie. Ann Oncol 2002; 13:1460-1468.
37. Cangiano T., Liao J., Naitoh J., et al. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immuno-therapy. J Clin Oncol 1999; 17:523-528.
38. Motzer RJ, Bacil J., Mariani T., et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20:2376-2381.
39. Upton M. P., Parker RA, Youmans A., et al. B. Renal cell carcinoma: histologic predictors of cytokine response. J Immunother 2005; 28:488-495.
40. Bui MHT, Seligson D., Han K., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9:802-811.
41. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin Cancer Res 2005; 11:3714-3721.
42. Pantuck AJ, Fang Z., Liu X., et al. Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23(16 suppl):386s (Abstract #4535).
43. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park) 2002; 16(11 suppl 13):4-10.